VCNX — Vaccinex Income Statement
0.000.00%
- $11.25m
- $9.50m
- $0.57m
Annual income statement for Vaccinex, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.523 | 0.625 | 0.9 | 0.275 | 0.57 |
Cost of Revenue | |||||
Gross Profit | 0.324 | 0.623 | 0.9 | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 32.5 | 29 | 22.5 | 20.2 | 23.5 |
Operating Profit | -32 | -28.3 | -21.6 | -19.9 | -22.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -31.9 | -28.9 | -22.4 | -19.8 | -20.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | -31.9 | -28.9 | -22.4 | -19.8 | -20.3 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -31.9 | -28.9 | -22.4 | -19.8 | -20.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -31.9 | -28.9 | -22.4 | -19.8 | -20.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -519 | -322 | -169 | -98 | -43.7 |